Essex Bio-Technology Limited (HKG:1061)
Hong Kong · Delayed Price · Currency is HKD 4.430
+0.010 (0.23%)
At close: Feb 13, 2026
Essex Bio-Technology Cash Flow Statement
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 313.18 | 307.22 | 275.26 | 225.41 | 345.97 | 218.93 |
Depreciation & Amortization | 50.31 | 50.71 | 54.26 | 36.43 | 27.44 | 24.69 |
Other Amortization | 7.54 | 5.17 | 5.61 | 5.48 | 5.54 | 2.91 |
Loss (Gain) From Sale of Assets | 0.47 | 0.48 | 2.22 | 0.29 | 0.28 | 0.22 |
Asset Writedown & Restructuring Costs | -0 | 2.88 | 5.05 | 38.84 | - | 11.81 |
Loss (Gain) From Sale of Investments | -7.27 | -0.93 | -12.72 | 4.76 | 31.9 | -21.78 |
Loss (Gain) on Equity Investments | 1.12 | 2.91 | 1.64 | 0.19 | - | - |
Stock-Based Compensation | - | - | - | 0.09 | 0.26 | 0.7 |
Provision & Write-off of Bad Debts | -0 | 7.19 | - | - | - | - |
Other Operating Activities | 10.63 | -13.87 | 59.51 | -21.22 | 58.13 | -15.94 |
Change in Accounts Receivable | 14.61 | 12.94 | -131.75 | 200.64 | -169.17 | 197.17 |
Change in Inventory | -6.53 | -2.25 | 16.79 | 9.49 | 8.68 | -40.11 |
Change in Accounts Payable | -16.79 | 17.08 | 70.9 | -105.56 | 80.58 | -65.01 |
Change in Other Net Operating Assets | -7.97 | -21.06 | -7.58 | -12.06 | 19.56 | -14.34 |
Operating Cash Flow | 359.29 | 368.47 | 339.21 | 382.79 | 409.16 | 299.24 |
Operating Cash Flow Growth | 13.75% | 8.63% | -11.39% | -6.45% | 36.73% | 28.51% |
Capital Expenditures | -105.83 | -44.4 | -21.03 | -89.49 | -90.05 | -97.1 |
Sale of Property, Plant & Equipment | 0.46 | 0.75 | 0.11 | 0.06 | 0.13 | 0.03 |
Cash Acquisitions | - | - | - | 3.47 | 0.03 | -2.17 |
Sale (Purchase) of Intangibles | -79.62 | -75.07 | -107.01 | -193.42 | -164.85 | -232.85 |
Investment in Securities | 0 | 2.33 | 0.37 | -3.05 | -2.94 | 6.95 |
Other Investing Activities | 8.13 | 12.94 | 73.22 | -9.69 | -6.11 | 9.22 |
Investing Cash Flow | -176.87 | -106.59 | -54.34 | -302.03 | -280.08 | -343.27 |
Long-Term Debt Issued | - | 106.9 | 42.74 | - | 55.45 | 212.99 |
Total Debt Issued | 185.06 | 106.9 | 42.74 | - | 55.45 | 212.99 |
Long-Term Debt Repaid | - | -183.38 | -284.23 | -84.12 | -57.59 | -21.59 |
Total Debt Repaid | -199.98 | -183.38 | -284.23 | -84.12 | -57.59 | -21.59 |
Net Debt Issued (Repaid) | -14.92 | -76.48 | -241.49 | -84.12 | -2.14 | 191.4 |
Issuance of Common Stock | - | - | - | - | 1.89 | - |
Repurchase of Common Stock | -1.35 | -1.13 | -12.59 | -14.79 | -8.68 | -4.38 |
Common Dividends Paid | -68.06 | -59.58 | -39.92 | -54.53 | -51.89 | -28.9 |
Other Financing Activities | -63.45 | -63.62 | -15.92 | -15.67 | -12.31 | -8.64 |
Financing Cash Flow | -147.79 | -200.81 | -309.92 | -169.11 | -73.13 | 149.49 |
Foreign Exchange Rate Adjustments | 7.49 | -13.75 | -8.58 | -39.49 | 15.61 | 20.98 |
Net Cash Flow | 42.12 | 47.32 | -33.64 | -127.85 | 71.55 | 126.44 |
Free Cash Flow | 253.46 | 324.07 | 318.17 | 293.29 | 319.12 | 202.14 |
Free Cash Flow Growth | -12.73% | 1.85% | 8.48% | -8.09% | 57.87% | 4.50% |
Free Cash Flow Margin | 14.75% | 19.41% | 18.32% | 22.26% | 19.49% | 20.67% |
Free Cash Flow Per Share | 0.45 | 0.56 | 0.53 | 0.49 | 0.53 | 0.34 |
Cash Interest Paid | 63.45 | 63.62 | 15.92 | 15.67 | 12.31 | 8.64 |
Cash Income Tax Paid | 54 | 62.28 | 18.32 | 49.2 | -9.53 | 43.34 |
Levered Free Cash Flow | 149.32 | 224.76 | 204.67 | 65.84 | 6.38 | -181.45 |
Unlevered Free Cash Flow | 152.73 | 228.57 | 211.68 | 73.01 | 12.15 | -180.56 |
Change in Working Capital | -16.69 | 6.72 | -51.64 | 92.52 | -60.35 | 77.7 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.